Skip to content

CHGB · Partner-reported service scope

Pathogen Detection (mNGS & tNGS)

Metagenomic and targeted next-generation sequencing for infectious disease, covering over 30,000 microorganisms and more than 2,000 antimicrobial resistance genes.

Partner-reported scope
30,000+ microorganisms
Method
mNGS · tNGS · nanopore
Public health scientist preparing a bacterial DNA fingerprinting test. Illustrative stock photograph.
Public health scientist preparing a bacterial DNA fingerprinting test

CHGB · Partner-reported

Service capabilities

The following scope is reported by the partner. Quantities describe the partner portfolio and do not represent VectorGene’s own track record.

Infection mNGS (DNA+RNA)
14,000+ bacteria, 7,100+ DNA viruses, 5,000+ RNA viruses, 1,300+ fungi, 200+ parasites.
Nanopore sequencing series
28,000+ microorganisms via metagenomics and targeted detection.
Targeted NGS (tNGS)
Faster turnaround for known pathogens.
Antimicrobial resistance profiling
2,000+ resistance genes.

Choose the method around the investigation.

Broad and targeted sequencing approaches need an agreed specimen and investigation scope. Programme planning should cover sample handling, laboratory controls, analysis versions and specialist reporting. Define how this service would sit alongside the institution’s existing microbiology and infectious-disease workflow.

CDC’s NGS Quality Initiative provides a sequencing-focused quality-management framework for clinical and public-health laboratories. Its resources address the system around a test, as well as the testing workflow.

CDC: The Next Generation Sequencing Quality Initiative

External references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.

Questions for the programme brief

  1. What is the investigation scope?

    Specify specimen types, target organisms or broad-detection objectives, and the existing tests the result would complement.

  2. How is the workflow controlled?

    Request contamination controls, validation evidence, database versions and rules for repeating or rejecting a run.

  3. Who interprets a finding?

    Agree clinical microbiology review, urgent communication and the handling of uncertain or unexpected signals.

What to prepare for review
  • Specimen and investigation brief
  • Current microbiology workflow
  • Validation, interpretation and escalation requirements

Working environments

Molecular testing and sequencing preparation.

Illustrative stock photography provides context for the people, processes and working environments behind this capability.

Three questions for the workflow

Each vial highlights one planning question. The drawing is an illustrative object.

Sample
What specimen and clinical question are being investigated?
Method
How are contamination controls and database versions recorded?
Interpretation
Who distinguishes a relevant finding from background signal?
All three review topics are shown.
Automated sample transport in a laboratory. Illustrative stock photograph.
Automated sample transport in a laboratory
Scientist inspecting a serological testing plate. Illustrative stock photograph.
Scientist inspecting a serological testing plate
Laboratory technicians reviewing a software platform. Illustrative stock photograph.
Laboratory technicians reviewing a software platform
Nocardia colonies on sheep blood agar. Illustrative stock photograph.
Nocardia colonies on sheep blood agar

Start a conversation

Discuss Pathogen Detection (mNGS & tNGS)

This service will be retained as context for your enquiry. Choose the platform or support area you want to develop at your institution.